Zura Bio Current Valuation vs. Book Value Per Share

ZURA Stock   2.78  0.02  0.72%   
Considering Zura Bio's profitability and operating efficiency indicators, Zura Bio Limited may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Zura Bio's ability to earn profits and add value for shareholders.
For Zura Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zura Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zura Bio Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zura Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zura Bio Limited over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zura Bio. If investors know Zura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zura Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zura Bio Limited is measured differently than its book value, which is the value of Zura that is recorded on the company's balance sheet. Investors also form their own opinion of Zura Bio's value that differs from its market value or its book value, called intrinsic value, which is Zura Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zura Bio's market value can be influenced by many factors that don't directly affect Zura Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zura Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zura Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zura Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Zura Bio Limited Book Value Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Zura Bio's current stock value. Our valuation model uses many indicators to compare Zura Bio value to that of its competitors to determine the firm's financial worth.
Zura Bio Limited is rated first in current valuation category among its peers. It is rated first in book value per share category among its peers . The ratio of Current Valuation to Book Value Per Share for Zura Bio Limited is about  80,369,956 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zura Bio's earnings, one of the primary drivers of an investment's value.

Zura Current Valuation vs. Competition

Zura Bio Limited is rated first in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 61.26 Billion. Zura Bio adds roughly 188.39 Million in current valuation claiming only tiny portion of equities under Health Care industry.

Zura Book Value Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Zura Bio

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
188.39 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Zura Bio

Book Value per Share

 = 

Common Equity

Average Shares

 = 
2.34 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Zura Book Value Per Share Comparison

Zura Bio is currently under evaluation in book value per share category among its peers.

Zura Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Zura Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zura Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zura Bio's important profitability drivers and their relationship over time.

Use Zura Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zura Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zura Bio will appreciate offsetting losses from the drop in the long position's value.

Zura Bio Pair Trading

Zura Bio Limited Pair Trading Analysis

The ability to find closely correlated positions to Zura Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zura Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zura Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zura Bio Limited to buy it.
The correlation of Zura Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zura Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zura Bio Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zura Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Zura Bio position

In addition to having Zura Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Emerging Markets ETFs Thematic Idea Now

Emerging Markets ETFs
Emerging Markets ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Zura Bio Limited offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zura Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zura Bio Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zura Bio Limited Stock:
Check out Your Current Watchlist.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
To fully project Zura Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Zura Bio Limited at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Zura Bio's income statement, its balance sheet, and the statement of cash flows.
Potential Zura Bio investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Zura Bio investors may work on each financial statement separately, they are all related. The changes in Zura Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zura Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.